Solara Active Pharma Sciences Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
Concerns
- Currently loss-making (EPS ₹-1.7)
- Negative return on equity (ROE -0.1%)
- Low capital efficiency (ROCE 4.9%)
- Premium to sector peers (P/E 715x vs industry 54.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SOLARA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 30.49% | 30.49% | 37.27% | 37.27% | 37.23% | 37.94% |
| FII | 16.62% | 15.80% | 14.00% | 14.25% | 14.67% | 14.63% |
| DII | 1.75% | 2.97% | 2.83% | 3.37% | 3.19% | 2.61% |
| Public | 51.14% | 50.73% | 45.89% | 45.11% | 44.92% | 44.82% |
Latest News
All newsSolara Active Pharma sees spurt in trading volume
*Solara Active Pharma sees spurt in trading volume* — A significant increase in trading volume has been observed in Solara Active Pharma Sciences Limited, prompting an inquiry from the NSE to ensure market transparency. The exchange has sought updated information from the company to safeguard investor interests. No major corporate event or disclosure has been announced yet. 📊 *STOCKS:* SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #VolumeSpurt
Solara Pharma discusses Q1FY26 financial results
*Solara Pharma discusses Q1FY26 financial results* in its investor call. The company reviewed performance for the quarter ended June 30, 2026, highlighting revenue of **₹182.4 Cr** and EBITDA at **₹34.1 Cr**. Management discussed margin trends and R&D outlay of **₹12.5 Cr**. Guidance for FY26 exports reiterated at **$115–120 Mn**. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
Solara receives rectification order from regulator
*Solara receives rectification order from regulator*. Solara Active Pharma Sciences has informed the exchange about a rectification order received, pertaining to regulatory compliance. The nature of the order is procedural and does not indicate any adverse action. No financial impact or operational changes have been disclosed. 📊 *STOCKS:* $SOLARA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulation